Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: anti-phosphatidylserine monoclonal antibodies - Avid Bioservices

Drug Profile

Research programme: anti-phosphatidylserine monoclonal antibodies - Avid Bioservices

Alternative Names: 2aG4; Anti-phosphatidylethanolamine monoclonal antibodies - Avid Bioservices; Anti-phospholipid monoclonal antibodies - Avid Bioservices; ch1N11; PGN-502; PGN-503; PGN-504; Truncated tissue factors - Avid Bioservices; Vascular targeting agents - Avid Bioservices

Latest Information Update: 28 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center; University of Texas Southwestern Medical Center
  • Developer Avid Bioservices; Peregrine Pharmaceuticals
  • Class Diagnostic agents; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Diagnostic imaging enhancers; Immunostimulants; Magnetic resonance imaging enhancers; Phosphatidylserine receptor antagonists; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Brain cancer; Breast cancer; Cancer; Malignant melanoma; Non-small cell lung cancer; Prostate cancer

Most Recent Events

  • 28 Nov 2018 No recent reports of development identified for preclinical development in Malignant-melanoma in USA (Parenteral)
  • 28 May 2018 No recent reports of development identified for preclinical development in Non-small-cell-lung-cancer in USA (Parenteral)
  • 12 Feb 2018 Oncologie acquires anti-phosphatidylserine monoclonal antibodies from Avid Bioservices
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top